Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 2294 • ACR Convergence 2025
Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
Carlota Navarro Joven¹, Silvia Piunno², Maryia Nikitsina³, CARMEN SAN JOSE MENDEZ⁴ and David A. Isenberg⁵, ¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ³University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ⁴Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ⁵University College London, London, United Kingdom
Background/Purpose: Sjögren’s syndrome is a heterogeneous autoimmune disease with no approved disease-modifying treatments. The aim of this systematic review was to evaluate primary Sjögren’s syndrome…
Abstract Number: 1683 • ACR Convergence 2025
Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
Pierre-Marie Duret¹, Pascal Schneider², Ludivine Robin³, Marine Vierling⁴, Nicolas Meyer⁵, Valerie Devauchelle⁶, Divi Cornec⁷, Alain SARAUX⁸, Jean Sibilia⁹, Raphaele Seror¹⁰, Yann Nguyen¹¹, Gaetane Nocturne¹², Laurent Mauvieux¹³, Laurent Miguet¹⁴, Xavier Mariette¹⁵ and Jacques-eric GOTTENBERG¹⁶, ¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²Université de Lausanne,Département de biochimie, Lausanne, Switzerland, ³Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁴Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ⁵Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ⁶UBO, Brest, France, ⁷LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁸CHU Brest, Brest, France, ⁹Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ¹⁰Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹¹Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹²University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ¹³Strasbourg University Hospital, Laboratory hematology, Strasbourg, France,CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, ¹⁴Strasbourg University Hospital, Laboratory hematology, Strasbourg, France, CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, ¹⁵Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁶Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Sjögren disease (SD) is a B cell driven systemic auto-immune disease, with a need for biomarkers to better assess disease activity, risk of lymphoma…
Abstract Number: 1396 • ACR Convergence 2025
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
Esra Sevimli¹, Berceste Polat², Busra Sari³, Can Akmansoy², Burcu Aksoy⁴, Omur Mumcu⁵, Hatice Kalender³, Aysegul Avcu⁶, Mustafa Erdogan⁷, Nur Sisman⁸, Farida Fortune⁹, Gonca Mumcu¹⁰ and Nevsun Inanc⁷, ¹¹Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ²Marmara University, Faculty of Dentistry, Istanbul, Turkey, ³Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Institute of Postgraduate Education, Department of Health Management, Istanbul, Turkey, ⁵Yeditepe University, Faculty of Dentistry, Istanbul, Turkey, ⁶Marmara University, Istanbul, Turkey, ⁷Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁹Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, London, United Kingdom, ¹⁰Faculty of Dentistry, Istanbul Okan University, Istanbul, Turkey
Background/Purpose: Patient-centred care and improvement of daily life are the main components in chronic disease management. The aim of the study was to determine associations…
Abstract Number: 1377 • ACR Convergence 2025
Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
Esen Akpek¹, Elizabeth Adamson², Lisa Shea², Federico Zazzetti³, Soumya Chakravarty⁴, Sandip Ranjan⁵, Ravi Potluri⁶ and Alexander Keenan², ¹Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center, Baltimore, MD USA, Baltimore, MD, ²Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Putnam Associates, Gurugram, India, Gurugram, India, ⁶Putnam Associates, Boston, MA, USA, Boston, MA
Background/Purpose: Sjögren’s disease (SjD) is a chronic systemic autoimmune disorder that imposes significant clinical, humanistic, and economic burdens on patients. It is associated with multiple…
Abstract Number: 0514 • ACR Convergence 2025
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Nicholas Bauer¹, Rufei Lu¹, Carla Guthridge¹, Tayte Stephens², Benjamin Jones³, Wade DeJager⁴, Susan Macwana¹, Caroline Shiboski⁵, Alan Baer⁶, Christopher Lessard¹, Astrid Rasmussen¹, Stephen Shiboski⁵, Judith James¹, Linda F. Thompson¹, Blake M. Warner⁷, A. Darise Farris¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma State University, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵University of California San Francisco, San Francisco, CA, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: Blood immunophenotyping reveals systemic immune alterations and therapeutically actionable molecular endotypes in Sjögren’s Disease (SjD). Reported changes include reduced memory B cells, plasmacytoid dendritic…
Abstract Number: 2489 • ACR Convergence 2025
Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
Kevin Chevalier¹, Benjamin Torreau², Marc Michel³, Bertrand Godeau³, Christian AGARD⁴, Thomas Papo⁵, Karim Sacré⁶, Brigitte Bader-Meunier⁷, Raphaele Seror⁸, Xavier Mariette⁹, Cacoub Patrice¹⁰, Ygal Benhamou¹¹, Hervé Levesque¹², Cécile goujard¹³, Olivier Lambotte¹⁴, Bernard Bonnotte¹⁵, Maxime Samson¹⁶, Félix Ackermann¹⁷, Jean Schmidt¹⁸, Pierre Duhaut¹⁸, Isabelle Kone-Paut¹⁴, Jean-Emmanuel Kahn¹⁹, Thomas Hanslik¹⁹, Nathalie Costedoat-Chalumeau²⁰, Benjamin Terrier²⁰, Alexis REGENT²¹, bertrand Dunogue²², Pascal Cohen²³, Véronique Le Guern²⁰, Eric HACHULLA²⁴, Benjamin Chaigne²² and Luc Mouthon²², ¹Université Paris Cité, Montrouge, France, ²Internal Medicine and Immunology, CHU Tours, Tours, France, ³Henri Mondor hospital, Créteil, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Bichat hospital, Paris, France, ⁶Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ⁷Necker hospital, Paris, France, ⁸Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ⁹Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹¹Internal Medicine, CHU Rouen, Rouen, France, ¹²Rouen hospital, Rouen, France, ¹³Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹⁴Bicêtre hospital, Kremlin Bicêtre, France, ¹⁵Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Foch hospital, Suresnes, France, ¹⁸Amiens hospital, Amiens, France, ¹⁹Ambroise Paré hospital, Boulogne, France, ²⁰Cochin hospital, Paris, France, ²¹Hopital Cochin, Paris, France, ²²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Approximately 25% of MCTD patients will meet…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 1681 • ACR Convergence 2025
Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Belén Serrano-Benavente⁷, Judit Font-Urgelles⁸, Angel Garcia-Aparicio⁹, Sara Manrique-Arija¹⁰, Jesús Alberto Garcia Vadillo¹¹, Ruth Lopez-Gonzalez¹², Javier Narváez¹³, Maria Beatriz Rodriguez¹⁴, Carlos Galisteo¹⁵, Jorge Juan Gonzalez Martin¹⁶, Paloma Vela Casasempere¹⁷, Rabadán Elena¹⁸, Antonio Naranjo¹⁹, Beatriz Paredes-Romero²⁰, Leyre Riancho-Zarrabeitia²¹, Sheila Melchor Diaz²², Irene Altabás-González²³, Sergi Heredia Martin²⁴, Clara Moriano²⁵, Mª Angeles Blazquez Cañamero²⁶, Paula Estrada-Alarcón²⁷, Enrique Judez²⁸, Nerea Alcorta Lorenzo²⁹, Javier Loricera³⁰, Rosalía Martínez Pérez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Hospital Regional Universitario Málaga, Malaga, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Zamora Health Complex, Salamanca, Spain, ¹³Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁵Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁶HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁸Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ¹⁹Hospital Dr Negrin, PALMAS DE GRAN CANARIA (LAS), Spain, ²⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²¹Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²²¹² de Octubre University Hospital, Madrid, Spain, ²³Complejo Hospitalario de Vigo, Vigo, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶Hospital Ramon y Cajal, Madrid, Spain, ²⁷Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁸Albacete University Hospital, Albacete, Spain, ²⁹University Hospital Donostia, san sebastian, Spain, ³⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: The association between Sjögren’s disease (SjD) and non-Hodgkin lymphoma (NHL) is well established, although reported standardized incidence ratios (SIRs) vary considerably across studies. In…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 1376 • ACR Convergence 2025
A Systematic Literature Review on the Economic Burden of Sjögren’s Disease
Nora Sandorfi¹, Lisa Shea², Alexander Keenan², Elizabeth Adamson², Federico Zazzetti³, Soumya Chakravarty⁴, Donna Gotshall⁵, Jyotika Gandhi⁶, Sandip Ranjan⁶ and Esen Akpek⁷, ¹University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Sjögren’s Disease Patient, Hickory, NC, USA, Hickory, NC, ⁶Putnam Associates, Gurugram, India, Gurugram, India, ⁷Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center, Baltimore, MD USA, Baltimore, MD
Background/Purpose: Sjögren’s disease (SjD) is a chronic systemic autoantibody driven disorder characterized by glandular dysfunction that typically presents with oral and ocular dryness, fatigue, and…
Abstract Number: 0513 • ACR Convergence 2025
Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
Massiel Jimenez Artiles¹, asim Khanfar², Pratibha Chaudhary³, Roshan Subedi⁴, Qi Wang⁵ and Anthony Ocon⁶, ¹Rhode Island Hospital, North Providence, RI, ²Rochester Regional Health, Rochester, NY, ³Rochester General Hospital, Rochester, NY, ⁴Medstar Washington Hospital Center, Washington, DC, ⁵Metrohealth System/Case Western Reserve University, Cleveland, OH, ⁶Rochester Regional Health, Fairport, NY
Background/Purpose: While Sjögren’s disease is commonly associated with anti-SSA (anti-Ro) and/or anti-SSB (anti-La) antibodies, these autoantibodies are not disease-specific and may be present in various…
Abstract Number: 2449 • ACR Convergence 2025
Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren’s Syndrome: An Analysis Using Japanese Inpatient Database
Hiroshi Shiba¹, Mikio Nakajima², Kaito Nakamura³, Yusuke Sasabuchi⁴, Hiroyuki Ohbe⁵, Yuya Kimura⁶, Tadahiro Goto⁷, Hiroki Matsui⁸, Kiyohide Fushimi⁹ and Hideo Yasunaga⁵, ¹Suwa central hospital, Chino, Japan, ²Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Hiroo, Tokyo, Japan, ³Department of Rheumatology, Dokkyo Medical University, Shimotsuga, Tochigi, Japan, ⁴Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁵Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁶Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Kanagawa, Japan, ⁸Department of Clinical Epidemiology and Health Economics, School of Public Health, Bunkyo-ku, Tokyo, Japan, ⁹Department of Health Policy and Informatics, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Neuromyelitis optica spectrum disorder (NMOSD) can coexist with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Due to overlapping clinical presentations and the rarity…
Abstract Number: 2292 • ACR Convergence 2025
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Sandra G Pasoto¹, Talita Ribeiro², Nadia Emi Aikawa³, Ana C Medeiros-Ribeiro¹, Bruno Borges², Andre Franco⁴, Henrique Silva², Eloisa Bonfa⁵ and Clovis Artur Silva⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
Abstract Number: 1682 • ACR Convergence 2025
Sjögren’s Disease Salivary Gland Fibroblast Subsets are Proinflammatory and Aberrantly Promote Pain
Sara McCoy¹, Rachael Bogle², michele larsen³, Li Chen⁴, thomas pranzatelli⁵, Paola Perez⁶, john chiorini⁷, Alan Baer⁸, A. Darise Farris⁹, Christopher Lessard⁹, Astrid Rasmussen⁹, Caroline Shiboski¹⁰, Stephen Shiboski¹⁰, Alexander Mikesell³, Zachary Campbell³, Alex Tsoi², Johann Gudjonsson¹¹ and Blake M. Warner¹², ¹University of Wisconsin–Madison, Madison, WI, ²University of Michigan, Holland, OH, ³University of Wisconsin, Madison, ⁴University of Michigan, Ann Arbor, ⁵NIH, Bethesda, ⁶NIDCR, Bethesda, MD, ⁷NIH, bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰University of California San Francisco, San Francisco, CA, ¹¹University of Michigan, Ann Arbor, MI, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Fibroblasts (fb) are increasingly recognized as dynamic signaling hubs in rheumatic disease, yet their contribution to Sjögren Disease (SjD) remains poorly defined. We dissect…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].